公司概述
Hims & Hers Health, Inc. functions as a consumer-first health and wellness platform that facilitates connections between individuals and licensed healthcare professionals across the United States, the United Kingdom, Canada, Germany, the Republic of Ireland, France, Spain, and other international markets. The company operates within the Healthcare sector, specifically classified under the Drug Manufacturers - Specialty & Generic industry, which implies a focus on developing and distributing specialized pharmaceutical products alongside direct-to-consumer services. Its current market capitalization stands at $4.50B, with trailing twelve-month revenue reaching $2.35B and an employee base of 2442 individuals supporting these operations. These valuation and revenue figures indicate that the company has achieved significant scale and market penetration, positioning it as a substantial player capable of leveraging its distribution network to serve a global patient population for various health conditions.
财务健康
The company reported revenue of $2.35B over the trailing twelve months, generating a net income of $128.37M and an EBITDA of $175.66M. The substantial gap between the $2.35B in revenue and the $128.37M in net income reveals a cost structure where operating expenses, including sales, general, and administrative costs, consume a significant portion of top-line growth before reaching the bottom line. Free cash flow for the period was $110.51M, which provides the company with financial flexibility to fund its expansion initiatives or manage capital expenditures without relying on external financing. In terms of profitability metrics, the gross margin is 73.8%, indicating highly efficient production or sourcing of its drug and wellness products; however, the operating margin of 2.7% and profit margin of 5.5% suggest that high fixed costs or aggressive marketing spend are compressing operational earnings. The balance sheet shows $577.49M in cash against $1.12B in debt, resulting in a debt-to-equity ratio of 207.16, which characterizes a highly leveraged balance sheet where debt obligations exceed equity capitalization. Despite the high leverage, the current ratio of 1.90 indicates that current assets are nearly double current liabilities, suggesting adequate short-term liquidity to meet obligations as they come due. Return on Equity stands at 25.2% while Return on Assets is 5.3%, revealing that management is effectively utilizing shareholder equity to generate returns, though the lower ROA relative to ROE reflects the impact of the company's significant debt load on asset efficiency.
估值评估
The stock carries a trailing P/E ratio of 38.73 compared to a forward P/E of 13.91, implying that the market currently prices in a significant expected improvement in future earnings relative to the historical performance. The price-to-book ratio is 8.30, indicating that the market values the company at more than eight times its net asset value, which suggests a substantial premium assigned to its intangible assets and growth prospects. Alternative valuation metrics such as the price-to-sales ratio of 1.92 and an EV/EBITDA of 28.72 provide additional context, suggesting the market is willing to pay a high multiple for sales given the expectation of future profitability expansion. Regarding price action, the 52-week high is $70.43 and the low is $13.74; without the specific current share price, the exact percentage deviation cannot be calculated, but the wide range highlights significant volatility within the trading year. The beta of 2.31 signifies that the stock price is more than twice as volatile as the broader market, meaning it tends to amplify market movements with high sensitivity to sector-specific or general economic shifts.
Growth & Income
Revenue growth year-over-year is 28.4%, while earnings growth is -17.4%, indicating that earnings are growing slower than revenue, which implies that top-line expansion is not yet translating into proportional bottom-line growth due to high operating leverage or increased costs. As the company does not pay a dividend, the dividend yield is N/A and the payout ratio is 0.0%, meaning the firm retains all earnings rather than distributing them to shareholders. Since the company is not a dividend payer, it reinvests its earnings into growth initiatives, such as expanding its healthcare professional network or developing new therapeutic offerings, rather than paying out cash. The overall growth and income profile presents a classic high-growth, no-dividend equity structure where capital is prioritized for scaling operations rather than providing current income to investors.